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Background and Objectives: Buckwheat (Fagopyrum esculentum) is a gluten-free grain with acclaimed benefi-
cial effects on human health. Our aim was to assess the effect of buckwheat products on intestinal/extra-intestinal 
symptoms and biochemical parameters in patients with Non-Celiac Gluten Sensitivity (NCGS). Methods and 
Study Design: A randomized, crossover trial with two intervention phases was conducted on 19 NCGS patients 
over a 12 week-period. The participants were assigned to consume products made from buckwheat or to maintain 
their normal gluten-free diet for 6 weeks in a random order. Symptoms due to NCGS were evaluated using two 
questionnaires. Results: During the intervention period with buckwheat products, patients experienced a signifi-
cant decrease in the severity of abdominal pain and bloating (p=0.03). In contrast, the control group showed a 
significant worsening trend for the majority of NCGS symptoms such as nausea, headache, joint/muscle pain, and 
attention disorders. The replacement diet with buckwheat products also resulted in a significant increase of serum 
magnesium (+4.7%) and a significant reduction in the circulating levels of some pro-inflammatory cytokines such 
as interferon gamma (-33.3%) and monocyte chemotactic protein-1 (-46.5%). Conclusion: The study supports 
the positive effects of buckwheat for NCGS patients, showing that this alternative cereal can contribute to the re-
duction of both negative gastro-intestinal and related symptoms, and nutritional deficiencies, and lead to an im-
provement in inflammatory profile. 
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INTRODUCTION 
Non-celiac gluten sensitivity (NCGS) is an emerging 
syndrome, affecting up to 6% of the general population in 
Western countries, although the exact prevalence is as yet 
unknown.1 NCGS consists of a combination of intestinal 
and/or systemic symptoms, similar to those of celiac dis-
ease (CD) and irritable bowel syndrome (IBS).2 The most 
frequent intestinal symptoms are bloating and abdominal 
pain, alternating bowel habits, and nausea. Additional 
extra-intestinal manifestations include exhaustion, lack of 
wellbeing, headaches, anxiety, “foggy mind”, arm/leg 
numbness, muscle or joint pain and depression.3 
Given that there are no serologic and histological 
markers available, an objective approach to NCGS diag-
nosis is unavailable to date. According to the London 
criteria, a diagnosis of NCGS is made in patients with 
negative immune allergy tests to wheat, negative celiac 
disease serology, normal duodenal histopathology and the 
reduction of symptoms under a gluten-free diet (GFD).1 
However, gluten is only one protein contained within  
 
wheat. Recent studies have been suggested that wheat 
proteins other than gluten, such as amylase trypsin inhibi-
tors (ATIs), can elicit immunomediate reactions (innate 
immunity).4 
Nevertheless, in NCGS gastro-intestinal (GI) and extra-
GI symptoms occur after gluten ingestion, and rapidly 
improve after its withdrawal from the diet. Therefore, a 
GFD seems to be the only effective therapy.2 On the other 
hand, people who adopt a GFD commonly experience 
deficiencies in essential nutrients and vitamins.5 In fact,
gluten-free products tend to be low in a wide range of 
important nutrients, including vitamin B, calcium, iron, 
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zinc, magnesium, and fiber.5 Moreover, sugar or fat are 
added to gluten-free substitute flours to make the prod- 
ucts more palatable, thereby leading to a high calorie con-
tent. Hence, the possibility of replacing wheat flour with 
grains that are naturally gluten-free may represent a 
healthier option.6 
The technological and nutritional properties of alterna-
tive cereals, as a replacement for wheat, have been inves-
tigated and it has been suggested that the use of these 
pseudo cereals could improve the intake of protein, iron, 
calcium and fibre.7-8 Among these gluten-free grains, 
buckwheat seems to be one of the most valuable in terms 
of nutritional composition.9 
There is no research available so far on the use of this 
alternative cereal for patients with NCGS. Therefore, the 
present dietary intervention trial was conducted with the 
aim of evaluating the impact of buckwheat on intesti-
nal/extra-intestinal symptoms and biochemical parame-
ters in NCGS patients. 
 
METHODS 
Study population 
Nineteen subjects with a diagnosis of NCGS were re-
cruited among the patients visiting the Unit of Allergolo-
gy and Clinical Immunology of the S. Giovanni di Dio 
Hospital, Florence. Inclusion criteria were as follows: (1) 
age >18 years, (2) presence of symptoms of NCGS, (3) 
absence of celiac disease, (4) negative allergy tests to 
wheat (according to guidelines for IgE mediate food reac-
tions)10 (5) negative for HLA DQ 2 and DQ8 (6) positive 
in the double-blinded, placebo-controlled crossover chal-
lenge (DBPC) clinical trials with gluten muffin.4,11 
Exclusion criteria included other significant gastroin-
testinal diseases (such as cirrhosis or inflammatory bowel 
disease); other clinically significant co-morbidities; BMI 
>35 or <18 kg/m2 (suggesting an abnormal diet or health 
status); excessive alcohol intake; pregnancy or breast-
feeding; inability to give written informed consent. 
 
Buckwheat products 
The buckwheat products employed in the study were pas-
ta, hard tacks, biscuits and buckwheat-flakes. All of them 
were gluten free according to the Codex Alimentarius 
Standard and were provided by PROBIOS srl (Calenzano, 
Florence, Italy). With the exception of pasta, which was 
100% buckwheat, the other items also contained whole 
rice flour, corn flour, almonds flour, quinoa flour and 
flaxseeds. The macronutrient composition of these prod-
ucts is presented in Table 1. Overall, participants received 
80 g of pasta per day, 60 g of hard tacks per day, 40 g of 
biscuits per day and 50 g of flakes per day. They were 
instructed not to consume any other cereal products 
throughout the experimental period of the study. 
 
Study design 
The present study was randomised, cross-over trial, with 
two intervention phases spanning a total of 12 weeks. 
Baseline data were collected during a 2-week run-in peri-
od. After the run-in period, eligible participants were ran-
domly assigned with a 1:1 ratio either to the experimental 
group or the control group. During the experimental peri-
od, patients were asked to substitute all gluten-free prod-
ucts, usually consumed, with a range of suitable commer-
cially-available buckwheat products that were provided 
for the study. On the contrary, during the control period, 
patients were asked to maintain their normal GFD. At the 
end of the first 6-week intervention phase, patients 
crossed over to the other treatment condition for the re-
maining 6 weeks of the study. Symptoms due to NCGS 
were evaluated using two questionnaires, which were 
compiled both at baseline and on a weekly basis for the 
duration of the study. Patients were instructed to maintain 
their normal dietary and lifestyle habits throughout the 
study, and not to change or take any medication without 
consulting the investigator.  
The study was performed in accordance with the Hel-
sinki II declaration. Written informed consent was ob-
tained from each participant before the initial screening 
visit and before randomization. The institutional review 
board at the University of Florence, aimed at protecting 
human participants, approved the study protocol (SPE 
13.115)  
. 
Data collection and measurements 
At baseline and at the end of the two intervention phases, 
respectively, all patients were examined between 7:00 
a.m. and 9:30 a.m. after an overnight fasting period. 
Moreover, each patient underwent an interview, accord-
ing to standardized methods, to obtain information about 
personal medical history, demographics, medication, and 
lifestyle habits. Physicians, using standardized protocols, 
conducted a physical examination and laboratory tests. 
Patients were asked not to engage in strenuous physical 
activity during the day before the examination. Anthro-
pometric measurements and body composition were made 
on entry to the study and at the end of the two phases. 
Weight and height were measured through use of a stadi-
ometer. Body mass index (BMI) was calculated as weight 
(kg)/height (m)2. The body composition was determined 
with a bioelectrical impedance analyser device (Tanita, 
model SC 330 P). 
Because of the absence of reliable biomarkers for 
NCGS, a symptomatic trend was measured using scores 
validated for functional diseases. In particular, NCGS 
 
Table 1. Macro-nutritional composition in 100 g buckwheat products used in the intervention study 
 
Product 
Energy 
(kJ) 
Energy 
(kcal) 
Fat 
(g) 
Carbohydrate 
(g) 
Protein 
(g) 
Dietary fibre 
(g) 
Salt 
(g) 
Saturatedfat 
(g) 
Total 
sugars (g) 
Pasta 1456 344 3.4 61.1 13.3 6 0.8 0.7 0.6 
Cakes 1543 369 4.0 68.4 11.1 7.4 0.5 0.8 0.2 
Flakes 1682 397 1.2 86 7.5 6 1.2 0.1 8.7 
Biscuits 1870 445 16 68 6.1 2.3 0.8 2.6 23 
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symptom frequency and severity were assessed using a 
modified version of two IBS-specific questionnaires: the 
Global Assessment of Improvement Scale (GAI)12 and 
the Symptom Severity Scale (SSS).13 Assessments were 
made at the start of each week for the entire duration of 
the respective intervention phases. The modified GAI 
Scale assessed NCGS symptoms using a 7-pointscale. 
The severity of abdominal pain, severity of abdominal 
distention, satisfaction with bowel habits, severity of 
headache, severity of exhaustion, severity of nausea, at-
tention disorder, muscle/joint pain, and quality of life was 
investigated in response to the following question: “Com-
pared to the way you felt before you entered the study, 
have your NCGS symptoms over the past 7 days been: 1) 
“Substantially Worse”, 2) ”Moderately Worse, 3) ”Slight-
ly Worse”, 4) ”No Change”, 5) ”Slightly Improved”, 
6) ”Moderately Improved” or 7) “Substantially Im-
proved”.   
The modified IBS-SSS is a multidimensional rating 
scale assessing overall NCGS severity on a Visual Ana-
logue Scale (VAS). An overall NCGS score was calculat-
ed from six items: pain severity, pain frequency, ab-
dominal bloating, bowel habit dissatisfaction, abdominal 
heaviness, and life interference. The modified IBS-SSS 
ranges from 0 to 600, with higher scores meaning more 
severe symptoms. SSS can be used to classify NCGS se-
verity as mild (<200), moderate (200–400), and severe 
(>400). SSS has been validated and found to be respon-
sive to changes in symptom severity; a change in 50 is 
considered to be adequate to detect a clinical improve-
ment.13 
A participant was defined as a subject who (1) an-
swered that, compared with prior to the intervention, his 
symptoms were either „moderately improved‟ or „sub-
stantially improved‟ to the GAI questions and (2) who 
reported a change of ≥50 points on the SSS. 
 
Laboratory analyses 
Blood sampling, after overnight fasting, was obtained 
from each participant. Lipid variables, blood glucose, 
serum electrolytes, serum minerals and liver enzymes 
were assessed by conventional methods. Venous blood 
samples were taken from the subjects by the study physi-
cian and collected into evacuated plastic tubes (Vacutain-
er). Samples obtained by centrifuging at 3,000 g for 15 
min at 4°C were stored in aliquots at - 80°C until analysis. 
 
Statistical analysis 
Statistical analysis was performed using the statistical 
package PASW 20.0 for Macintosh (SPSS, Inc.). All var-
iables were checked for a normal distribution before data 
analysis. Data were expressed as arithmetic means and 
standard deviations for normally distributed variables and 
as medians and ranges for non-normally distributed data. 
The Mann–Whitney U test was used for testing the differ-
ences between the groups. All data were treated as paired 
samples from a crossover study. The two interventions 
were analyzed by taking into account both periods in the 
two groups of subjects at different stages. A general line-
ar model for repeated measurements, with adjustments for 
age and sex, was used to compare the effect of the two 
different treatments. A p value <0.05 was considered to 
indicate statistical significance. 
 
RESULTS 
The median age of the study population (18 women; 1 
man) was 44 (range 28-65) years and the mean body mass 
index was 23.7±5. Three patients were defined as smok-
ers, and one was hypertensive under an optimal therapeu-
tic control. Baseline questionnaires for evaluating the 
severity of symptoms related to NCGS showed a moder-
ate severity in all the participants (total score for SSS: 
261±153, with a score ranging from 0 to 600). In particu-
lar, 37% had mild, 37% moderate, and 26% severe NCGS 
symptoms.  
With regard to the gastrointestinal symptoms, the most 
frequent were bloating (53%) and abdominal pain (47%). 
About one-third of the patients reported abdominal heavi-
ness, while 37% had alternating bowel habits. The most 
frequent extra-intestinal manifestations were joint/muscle 
pain and exhaustion, reported by 68% and 63%, respec-
tively. No statistically significant differences between the 
two randomized groups of intervention with regard to age, 
demographic characteristics, and pain scores were ob-
served (data not reported). 
 
Modifications of symptoms 
The changes in gastrointestinal and extra-intestinal 
symptoms were compared from baseline to the end of the 
intervention periods using a general linear model adjusted 
for age and sex. The SSS-score showed that patients 
consuming buckwheat products reported a significantly 
improved score at the end of the intervention period, 
compared with those who maintained their normal eating 
habits. In particular, during the buckwheat period, the 
severity score of abdominal pain significantly decreased 
from 41.3±30.8 at baseline to 31.1±25.3 at week 6 
(p<0.05) (Figure 1), and a significant trend of reduction in 
the severity of bloating was observed (p<0.05) (Figure 2).  
Eleven (58%) patients reported an improvement of 
more than 50 points according to the SSS-score, after 
consumption of the buckwheat products, compared with 
only 4 (21%) patients after the control period. In addition, 
 
 
 
Figure 1. Change in the SSS-score for severity of abdominal 
pain in the buckwheat and control groups over a 6-week 
period. *The reduction in the severity of symptoms was 
significant (p<0.05) 
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we observed that during the buckwheat intervention peri-
od patients with moderate and severe NCGS manifesta-
tions at baseline were more likely to indicate significant 
improvements in NCGS symptoms (change in SSS-score: 
-88 (CI -167; -8) p<0.05), compared with patients with 
mild NCGS symptoms at baseline (change in SSS-score: 
38 (-29; 105) p=0.2) (Figure 3).   
The GAI questionnaire also showed a trend for an im-
provement in NCGS symptoms in patients who consumed 
the buckwheat products but this change did not reach sta-
tistical significance. In contrast, the control group showed 
a significant trend of worsening for the majority of the 
NCGS symptoms: nausea (5.4±1.5 at baseline vs 4.1±0.9 
at week 6; p<0.05), headache (5.1±1.4 vs 3.8±1.0; 
p<0.05), joint/muscle pain (4.6±1.7 at baseline vs 6 
3.3±1.3 at week 6; p<0.05), attention disorder (4.8±1.5 at 
baseline vs 3.9±0.7 at week 6; p<0.05), and satisfaction 
with stool consistency (4.8±1.4 at baseline vs 3.9±1.6 at 
week 6; p<0.05). 
Four (21%) patients responded positively for the symp-
tom of joint/muscle pain after the buckwheat-product 
intervention period, compared with only 1 (5%) subject 
after the control period. Similarly, 3 (16%) patients re-
ported to have reduced nausea and lack concentration at 
the end of the buckwheat-product intervention period, 
whereas only 1 (5%) subject reported a significant ame-
lioration after the control period. 
 
Changes in other measurements 
At the end of the intervention period, anthropometrical 
measurements did not change significantly with respect to 
baseline in both groups (data not reported). With regard 
to the biochemical parameters, no significant difference 
was observed for the vast majority of the investigated 
parameters, after both dietary intervention periods. How-
ever, significant improvements in the circulating levels of 
magnesium (+0.08 mg/dL (+4.7%); p<0.05) were report-
ed after the intervention period with only the buckwheat 
products (Table 2). 
In addition, the circulating levels of some pro-
inflammatory cytokines such as interferon gamma and 
monocyte chemotactic protein-1 decreased significantly (-
9.2 pg/mL (-33.3%); -20.6 pg/mL (-46.5%), respectively; 
p<0.05) after the intervention phase with the buckwheat 
products (Table 3). This effect was not evident after the 
consumption of control GFD phase. 
 
DISCUSSION 
The aim of the current study was to assess the effect of 
buckwheat products on gastro-intestinal manifestations, 
related extra-gastro-intestinal symptoms, as well as bio-
chemical parameters in patients with NCGS. After the 6-
week buckwheat intervention period, the majority of pa-
tients reported an overall significant reduction in the se-
verity of the two most frequent symptoms such as bloat-
ing and abdominal pain. Conversely, significant worsen-
ing was shown during the control period, when patients 
returned to their normal GFD. With regard to the bio-
chemical parameters, there were no diet-specific changes 
in any biomarker, except for circulating levels of magne-
sium, that increased after the buckwheat intervention pe-
riod. 
Because of their suspected involvement in NCGS path-
ogenesis,14 inflammatory cytokine levels were also evalu-
ated. Patients experienced a significant decrease in both 
interferon gamma and monocyte chemotactic protein-1 
levels after the intervention period, but further research is 
needed to clarify this issue. 
This is the first dietary intervention trial that assessed 
the efficacy of buckwheat products on gastrointestinal 
symptoms, biochemical parameters and the inflammatory 
profile among NCGS patients. Over the last few years, 
there has been a resurgence in research interest regarding 
NCGS, as demonstrated by several scientific contribu-
tions on this topic.15-18 Nevertheless, our knowledge is 
still limited, and there are many unresolved points war-
ranting clarification. On the one hand, NCGS is a symp-
tom-based condition, in which diagnosis remains highly 
presumptive, being exclusively based on clinical criteria 
and on exclusion of celiac disease and wheat allergy. On 
the other hand, despite the general agreement that gluten 
exclusion improves NCGS symptoms,19 growing evi-
dence indicates that gluten is not the only emerging trig-
ger. Other components are likely to play a relevant role in 
the pathogenesis of this syndrome.20 In addition, several 
double-blind trials underlined the possibility that many 
 
 
Figure 2. Change in the SSS-score for severity of bloating in 
the buckwheat  and control  diet-treated groups over a 6-week 
period. *The trend of reduction in the severity of symptom was 
significant (p<0.05). 
 
 
 
 
Figure 3. Change in total score for SSS in patients with mild 
NCGS symptoms at baseline compared to patients with 
moderate and severe NCGS manifestations at baseline. *The 
reduction in the severity of symptoms was significant (p<0.05). 
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Table 2. Modifications of biochemical parameters 
 
Variables 
Buckwheat 
p** 
Control 
p** 
Pre Post Change Pre Post Change 
Total cholesterol (mg/dL) 205.9±7.1 196.4±6.6 -9.5 (-26.7; 7.7) 0.26 196.1±6.3 196.5±7.1 0.4 (-12.9; 13.8) 0.95 
LDL-cholesterol (mg/dL) 111.7±6.0 112.2±6.3 -3.6 (-10.5; 6.6) 0.28 108.8±5.0 109.3±6.1 1.3 (-5.8; 8.5) 0.70 
HDL-cholesterol (mg/dL) 72.0±4.3 68.4±4.1 0.5 (-12.9; 13.9) 0.98 69.9±3.5 71.3±3.2 0.4 (-8.1; 8.9) 0.91 
Triglycerides (mg/dL) 84.2±10.8 84.0±0.9 -0.2 (-27.0; 26.7) 0.99 92.5±12.4 84.5±10.0 -8.0 (-34.0; 18.0) 0.52 
Blood glucose (g/L) 0.79±0.02 0.82±0.02 0.03 (-0.01; 0.07) 0.16 0.82±0.02 0.79±0.02 -0.03 (-0.07; 0.01 0.14 
Magnesium (mg/dL) 1.93±0.03 2.02±0.02* 0.08 (0.02; 0.15) 0.01 1.99±0.03 2.02±0.04 0.02 (-0.09; 0.14) 0.69 
 
Data are reported as mean and standard deviation. 
*
p<0.05 for paired t-test. 
**
p for general linear model adjusted for age and gender. 
 
 
Table 3. Modifications of inflammatory profile 
 
Variables 
Buckwheat 
p** 
Control 
p** 
Pre Post Change Pre Post Change 
IL-1ra (pg/mL) 32.8±25.3 36.2±27.0  3.40 (-6.88; 13.7)  0.49   29.4±21.4 35.3±26.4   5.87 (-5.06; 16.8) 0.27  
IL-4 (pg/mL) 0.34±0.25   0.27±0.22 -0.07 (-0.19; 0.04)  0.18  0.32±0.30  0.28±0.26  -0.04 (-0.12; 0.04)  0.26 
IL-6 (pg/mL) 3.6±3.1   2.4±1.6 * -1.18 (-2.42; 0.07)  0.06  3.6±4.0 3.1±2.8  0.52 (-1.85; 0.80) 0.42 
IL-8 (pg/mL)  23.0±26.6 21.2±35.9  -1.82 (-12.3; 8.7) 0.72 37.5±43.1  28.2±57.5  -9.29 (-33.7; 15.1) 0.43 
IL-10 (pg/mL) 9.9±5.0 11.4±8.4 1.44 (-2.29; 5.18) 0.43  11.1±8.1 10.2±5.1   10.2 (7.6; 12.8) 0.45 
IL-12 (pg/mL) 15.0±7.5 12.7±6.6 -2.24 (-5.08; 0.60) 0.11 14.0±6.7 13.2±5.9 -0.84 (-2.69; 1.00) 0.35 
VEGF (pg/mL) 150.4±147.7   112.5±82.1 -38.0 (-106.8; 30.8) 0.26   191.1±164.3 153.9±155.2 *  -37.2 (-70.5;  -3.8)   0.03 
IFN-gamma (pg/mL) 27.6±21.5 18.4±7.2 * -9.16 (-18.5; 0.14) 0.05 24.0±17.6 19.6±12.2 -4.35 (-11.0; 2.26) 0.18 
MCP-1 (pg/mL) 44.3±27.8 23.7±12.1 * -20.6 (-33.6; -7.58) 0.01 36.3±25.5 26.8±16.9 -9.48 (-24.0; 5.0) 0.19 
TNF-alpha (pg/mL) 7.7±4.7 7.1±4.1 -0.62 (-3.72; 2.49) 0.68 7.2±7.1 6.5±7.2 -0.69 (-5.05; 3.66) 0.74 
 
IL-1ra: interleukin-1ra; IL-4: interleukin-4; IL-8: interleukin-8; IL-10: interleukin-10; IL-12: interleukin-12; VEGF: Vascular Endothelial Growth Factor; INF-gamma: interferon-gamma; MCP-1: Monocyte Chemo-
tactic Protein-1; TNF-alpha: Tumor Necrosis Factor-alpha. 
Data are reported as mean and standard deviation.  
*
p<0.05 for paired t-test.  
**
p for general linear model adjusted for age and gender. 
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patients with a self-diagnosis of food hypersensitivity 
display an imaginary syndrome that is caused by the 
nocebo effect of gluten ingestion.21,22 
To date, five placebo-controlled dietary interventions in 
patients with presumptive NCGS have been published 
with contrasting results in terms of the culprit agent.21-27 
In the study by Biesiekierski et al23 patients who received 
the gluten challenge reported worsening of the abdominal 
symptoms than those who received the placebo. Similarly, 
in a second trial, conducted by the same research group, 
no differences among high-gluten, low-gluten or placebo 
challenge were demonstrated.24 However, in the latter 
study, patients showed a significant clinical improvement 
during the run-in period of the study, i.e. when they were 
under a low FODMAPs-diet (Fermentable Oligo-Di-
Monosaccharides and Polyols). Therefore, the possibility 
that NCGS patients could be sensitive to FODMAPs has 
been hypothesized, and it has been later supported by the 
results of other two most recent studies25,27 that reported 
an improvement in patients with gluten-free flour sensi-
tivity when a low FODMAPs-diet was recommended.28 
Actually, dietary management of patients with NCGS 
still presents unanswered questions concerning elimina-
tion diets, supplements, and foods that may help symp-
toms of the disorder. Gluten-free diet is the first recom-
mended dietary change for these patients, but an increas-
ing number of patients shift to gluten-free products with-
out any precise medical advice or indication, so likely 
causing nutritional deficiencies. Indeed, a GFD could be 
low in nutrients, whereas commercially available gluten-
free products are generally abundant in chemical addi-
tives and preservatives, a potential cause of functional 
gastrointestinal symptoms.5 
Buckwheat (Fagopyrum esculentum) is a promising al-
ternative gluten-free product, which is characterized by a 
highly nutritive composition.29,30 Buckwheat is an excel-
lent source of manganese, copper, magnesium, phospho-
rus, vitamins and fibre.6 This alternative cereal contains 
several polyphenolic antioxidant compounds with signifi-
cant health-promoting actions, such as rutin, tannins and 
catechin. In addition, the proteins in buckwheat are repre-
sentative of high-quality proteins, containing all the es-
sential amino acids, including lysine.31 As part of a 
healthy way of eating, buckwheat can significantly lower 
the risk of cardiovascular disease, obesity and type 2 dia-
betes.32 
Although results are promising, the number of partici-
pants represents a limitation in this study. Further and 
larger studies are needed before drawing any firm conclu-
sions on the effects of buckwheat products on NCGS pa-
tients. We are aware that changes in dietary and/or life-
style habits could have affected the investigated parame-
ters. However, before initiating the experimental trial, all 
patients were instructed by physicians, and by an expert 
dietician, to maintain their usual lifestyle habits.  
In conclusion, the present study provided evidence for 
the positive effects of buckwheat in NCGS, thereby 
showing that this alternative cereal represents a dietary 
option for patients with NCGS. These results are certainly 
interesting, but further research is necessary to better in-
vestigate whether the use of alternative cereals are effec-
tive in reducing symptom severity and nutritional defi-
ciencies in the diets of gluten sensitive patients. 
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